Nemolizumab (Nemluvio – Galderma), a subcutaneously injected interleukin-31 (IL-31) receptor antagonist, has been approved by the FDA for use in combination with topical corticosteroids and/or calcineurin inhibitors for treatment of moderate to severe atopic dermatitis in patients ≥12 years old whose disease is not adequately controlled with topical prescription drugs. It is the first IL-31 receptor antagonist to be approved in the US for this indication. Nemolizumab was approved earlier for treatment of prurigo nodularis in adults.
THE DISORDER — Atopic dermatitis (also known as...
- Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
- Tirzepatide (Zepbound) for Obstructive Sleep Apnea
- In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo
- In Brief: Anaphylaxis with Glatiramer Acetate
- Comparison Chart: Interleukin (IL) Receptor Antagonists for Atopic Dermatitis (online only)
- Cosibelimab (Unloxcyt) for Cutaneous Squamous Cell Carcinoma (online only)
- Ensartinib (Ensacove) for Non-Small Cell Lung Cancer (online only)
- Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
- Drugs for Irritable Bowel Syndrome
- Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
- Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
- Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
RELEASE
The FDA has approved suzetrigine (Journavx – Vertex), a selective sodium channel blocker, for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years.
STANDARD TREATMENT ― Nonopioid drugs are preferred for treatment of pain. In patients with moderate to severe acute pain, use of an NSAID plus acetaminophen may be at least as effective as an oral opioid combined with acetaminophen or even an injected opioid. NSAIDs can increase the risk of bleeding and can cause cardiovascular, gastrointestinal, and renal adverse effects.
As-needed use of a short-acting full opioid agonist may be required for severe acute pain. Opioids should be given in …